Clinical Trial Update: A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 pilot trial evaluated a tumor cell vaccine in high-risk solid tumor patients after stem cell transplantation, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Sarcoma
• Wilms Tumor

Drugs mentioned

• Tumor Cell Vaccine

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Sarcoma, Neuroblastoma | Phase 2 | Status: COMPLETED